145 related articles for article (PubMed ID: 25153380)
1. KLKs and their hormone-like signaling actions: a new life for the PSA-KLK family.
Hollenberg MD
Biol Chem; 2014 Sep; 395(9):915-29. PubMed ID: 25153380
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier.
Oikonomopoulou K; Diamandis EP; Hollenberg MD
Biol Chem; 2010 Apr; 391(4):299-310. PubMed ID: 20180639
[TBL] [Abstract][Full Text] [Related]
3. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs).
Ramsay AJ; Reid JC; Adams MN; Samaratunga H; Dong Y; Clements JA; Hooper JD
Biol Chem; 2008 Jun; 389(6):653-68. PubMed ID: 18627286
[TBL] [Abstract][Full Text] [Related]
4. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
5. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer.
Hollenberg MD; Oikonomopoulou K; Hansen KK; Saifeddine M; Ramachandran R; Diamandis EP
Biol Chem; 2008 Jun; 389(6):643-51. PubMed ID: 18627296
[TBL] [Abstract][Full Text] [Related]
6. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
7. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches.
Veveris-Lowe TL; Kruger SJ; Walsh T; Gardiner RA; Clements JA
Semin Thromb Hemost; 2007 Feb; 33(1):87-99. PubMed ID: 17253195
[TBL] [Abstract][Full Text] [Related]
8. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer.
Figueroa CD; Molina L; Bhoola KD; Ehrenfeld P
Biol Chem; 2018 Sep; 399(9):937-957. PubMed ID: 29885274
[TBL] [Abstract][Full Text] [Related]
9. Evolutionary history of tissue kallikreins.
Pavlopoulou A; Pampalakis G; Michalopoulos I; Sotiropoulou G
PLoS One; 2010 Nov; 5(11):e13781. PubMed ID: 21072173
[TBL] [Abstract][Full Text] [Related]
10. Activation and activity of glycosylated KLKs 3, 4 and 11.
Guo S; Briza P; Magdolen V; Brandstetter H; Goettig P
Biol Chem; 2018 Sep; 399(9):1009-1022. PubMed ID: 29975661
[TBL] [Abstract][Full Text] [Related]
11. Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer.
Pampalakis G; Sotiropoulou G
Biochim Biophys Acta; 2007 Sep; 1776(1):22-31. PubMed ID: 17629406
[TBL] [Abstract][Full Text] [Related]
12. Kallikreins as biomarkers for prostate cancer.
Hong SK
Biomed Res Int; 2014; 2014():526341. PubMed ID: 24809052
[TBL] [Abstract][Full Text] [Related]
13. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.
Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW
J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829
[TBL] [Abstract][Full Text] [Related]
14. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers.
Emami N; Diamandis EP
Clin Chem; 2008 Oct; 54(10):1600-7. PubMed ID: 18687738
[TBL] [Abstract][Full Text] [Related]
15. Activation of membrane-bound proteins and receptor systems: a link between tissue kallikrein and the KLK-related peptidases.
Dong Y; Harrington BS; Adams MN; Wortmann A; Stephenson SA; Lisle J; Herington A; Hooper JD; Clements JA
Biol Chem; 2014 Sep; 395(9):977-90. PubMed ID: 24854540
[TBL] [Abstract][Full Text] [Related]
16. Proteinases as hormones: targets and mechanisms for proteolytic signaling.
Hansen KK; Oikonomopoulou K; Baruch A; Ramachandran R; Beck P; Diamandis EP; Hollenberg MD
Biol Chem; 2008 Aug; 389(8):971-82. PubMed ID: 18979623
[TBL] [Abstract][Full Text] [Related]
17. KLK-targeted Therapies for Prostate Cancer.
Hannu K; Johanna M; Ulf-Håkan S
EJIFCC; 2014 Sep; 25(2):207-18. PubMed ID: 27683469
[TBL] [Abstract][Full Text] [Related]
18. Targeting kallikrein-related peptidases in prostate cancer.
Mavridis K; Avgeris M; Scorilas A
Expert Opin Ther Targets; 2014 Apr; 18(4):365-83. PubMed ID: 24571737
[TBL] [Abstract][Full Text] [Related]
19. Targeting the kallikrein-related peptidases for drug development.
Sotiropoulou G; Pampalakis G
Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
[TBL] [Abstract][Full Text] [Related]
20. Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function?
Tan OL; Whitbread AK; Clements JA; Dong Y
Biol Chem; 2006 Jun; 387(6):697-705. PubMed ID: 16800730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
